RajivPatniMD

Physician

Dr. Patni is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I am a cardiologist, who has been focused on clinical drug development in the pharmaceutical / biotechnology industry. To date, I have been involved in approximately 20 drug development programs, including dofetilide, quinapril, amlodipine, sildenafil, aliskiren, and macitentan. My approach has been partnering with academia and the FDA to design and execute pragmatic yet robust clinical trials to ultimately inform the creation of product labels, that are truthful and clinically relevant. In this way, the product label can inform responsible and appropriate utilization by the prescribing physician.

Montefiore Medical Center/Albert Einstein College of Medicine (Montefiore)Fellowship, Cardiovascular Disease, 1998 - 2000
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1995 - 1998
Icahn School of Medicine at Mount SinaiInternship, Transitional Year, 1994 - 1995
Icahn School of Medicine at Mount SinaiClass of 1994

PubMed

315 citations
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Murray Epstein, Gordon H. Williams, Myron H. Weinberger, Andrew J. Lewin, Scott Krause
Clinical Journal of the American Society of Nephrology. 2006-09-01
29 citations
Sustained Improvement in Flow-Mediated Vasodilation After Short-Term Administration of Dobutamine in Patients With Severe Congestive Heart Failure
Mrugesh B. Patel, Ilya V. Kaplan, Rajiv N. Patni, Daniel Levy, Joel A. Strom
Circulation. 1999-01-12
7 citations
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Jeffrey A. Cohen, Samuel F. Hunter, Theodore R Brown, Mark Gudesblatt, Ben Thrower
Multiple Sclerosis. 2019-04-01

Portola Pharmaceuticals Announces Results Demonstrating Andexxa® Was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related BleedsMarch 16th, 2020
Portola Pharmaceuticals Unveils Data on Andexxa in Patients with Multiple Types of Factor Xa Inhibitor-Related BleedsMarch 16th, 2020
New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa InhibitorsMarch 5th, 2020
Join now to see all